Company: HMDCF
Filing Date: 2025-03-19
Form Type: 20-F
Source: 0001410578-25-000377
Chunk: 698

Company: HUTCHMED (China) Ltd
Filing Date: 2025-03-19
Form: 20-F
Item: Item 16K
Chunk 698
---
 (15,995)       (17,022)       (16,738)  
  Profit for the year                                               92,929         95,463         99,683  

The accompanying notes are an integral part of these consolidated financial statements.

F-59

Table of Contents

Shanghai Hutchison Pharmaceuticals Limited

Consolidated Statements of Comprehensive Income

(in US$’000)

                                                                                                       Year Ended December 31,                            
                                                                                                                          2024        2023          2022  
 ──────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────
  Profit for the year                                                                                                   92,929      95,463        99,683  
  Other comprehensive income that has been or may be reclassified subsequently to profit or loss:                                                         
  Exchange translation differences                                                                                       1,008         755         3,332  
  Other comprehensive (loss)/income that will not be reclassified to profit or loss:                                                                      
  Exchange translation differences                                                                                     (4,814)       1,565      (19,913)  
  Total comprehensive income                                                                                            89,123      97,783        83,102  

The accompanying notes are an integral part of these consolidated financial statements.

F-60

Table of Contents

Shanghai Hutchison Pharmaceuticals Limited

Consolidated Statements of Financial Position

(in US$’000)

                                                               December 31,               
                                                     Note              2024         2023  
 ──────────────────────────────────────────────────────────────────────────────────────────
  Assets                                                                                  
  Current assets                                                                          
  Cash and cash equivalents                            10            48,160       19,129  
  Short-term investment                                10             2,718            —  
  Trade and bills receivables                          11            20,011       15,601  
  Other receivables, prepayments and deposits          12             2,345        2,269  
  Inventories                                          13           140,473      164,026  
  Total current assets                                              213,707      201,025  
  Property, plant and equipment                        14            50,671       55,101  
  Right-of-use assets                                  15               561        1,092  
  Leasehold land                                                      5,654        5,967  
  Other intangible assets                                             2,959        3,348